Leslie Dvorak
Women's Health · Omaha, NENPI 1265422562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,655 of the $64,769 with a category attached, or 75.1%. Gilead accounts for 65.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $39,037, more than ten times the $1,102 reported in 2021. Among women's health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $280.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$43K
- Organon$19K
- AbbVie$938
- Johnson & Johnson$287
- Otsuka America Pharmaceutical, Inc.$283
- Alkermes, Inc.$269
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$48,65575%
- Travel & lodging$10,51116%
- Food & beverage$5,5549%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 108 | $42,635 |
| Organon | 45 | $19,192 |
| AbbVie | 17 | $938 |
| Johnson & Johnson | 4 | $287 |
| Otsuka America Pharmaceutical, Inc. | 4 | $283 |
| Alkermes, Inc. | 5 | $269 |
| Viiv Healthcare Company | 8 | $259 |
| Ironshore Pharmaceuticals Inc. | 3 | $170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $144 |
| Antares Pharma, Inc. | 17 | $131 |
| Harmony Biosciences LLC | 1 | $125 |
| Noven Therapeutics, LLC | 1 | $121 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,769 in reported general payments places this provider in the 95th percentile of 60 women's health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol Valerate | 15 | $2,255 |
| Testosterone Cypionate | 18 | $939 |
| Estradiol | 22 | $652 |
| ProgesteroneProgesterone, Micronized | 19 | $593 |
| Bicalutamide | 15 | $390 |
| Spironolactone | 13 | $374 |
| Minocycline Hcl | 13 | $230 |
| Minoxidil | 14 | $82 |
Paid to pharmacies, not to this prescriber.
Other women's health in Omaha
- Sonia SublettOmaha$8K
- Jessica SiemersOmaha$4K
- Emily BlanchardOmaha$3K
- Lisa PatrickOmaha$3K
- Ashley SiegmanOmaha$2K
- Rebecca LeadersOmaha$1K
- Brenda HerrodOmaha$930
- Catherine MagdalenoOmaha$869
- Hilary MuhleOmaha$546
- Breanne PflanzOmaha$378
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.